货号:A133052
同义名:
CT99021; Laduviglusib
Laduviglusib (CHIR-99021)是一种有效、选择性且具有口服活性的 GSK-3α/β 抑制剂,可用作细胞疗法中的辅助试剂。CHIR99021促进人类诱导多能干细胞 (iPS 细胞) 分化为胰岛素生成细胞,促进人类 ES 细胞和 iPS 细胞分化为心肌细胞。CHIR99021与 SB431542 和人类重组 LIF 共同作用下,从人类 ES 细胞生成并维持原始神经干细胞。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | GSK-3 ↓ ↑ | GSK-3α ↓ ↑ | GSK-3β ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AZD2858 |
+
GSK-3, IC50: 68 nM |
99% | |||||||||||||||||
| Bikinin | ✔ | 99%+ | |||||||||||||||||
| GSK 3 Inhibitor IX |
++++
GSK-3, IC50: 5 nM |
99%+ | |||||||||||||||||
| AZD1080 |
+++
GSK-3α, IC50: 6.9 nM |
++
GSK-3β, IC50: 31 nM |
99%+ | ||||||||||||||||
| BIO-acetoxime |
+++
GSK-3α, IC50: 10 nM |
+++
GSK-3β, IC50: 10 nM |
95% | ||||||||||||||||
| SB-216763 |
++
GSK-3α, IC50: 34.3 nM |
++
GSK-3β, IC50: ~34.3 nM |
98% | ||||||||||||||||
| SB 415286 |
+
GSK-3α, IC50: 78 nM |
+
GSK-3β, IC50: ~78 nM |
99%+ | ||||||||||||||||
| CHIR-98014 |
++++
GSK-3α, IC50: 0.65 nM |
++++
GSK-3β, IC50: 0.58 nM |
98% | ||||||||||||||||
| LY2090314 |
++++
GSK-3α, IC50: 1.5 nM |
++++
GSK-3β, IC50: 0.9 nM |
99%+ | ||||||||||||||||
| CHIR 99021 |
+++
GSK-3α, IC50: 10 nM |
++++
GSK-3β, IC50: 6.7 nM |
99%+ | ||||||||||||||||
| TDZD-8 |
+
GSK-3β, IC50: 2 μM |
99%+ | |||||||||||||||||
| Indirubin |
+
GSK-3β, IC50: 0.6 μM |
98% | |||||||||||||||||
| IM-12 |
++
GSK-3β, IC50: 53 nM |
98% | |||||||||||||||||
| TWS119 |
++
GSK-3β, IC50: 30 nM |
99% | |||||||||||||||||
| 1-Azakenpaullone |
+++
GSK-3β, IC50: 18 nM |
99%+ | |||||||||||||||||
| AR-A014418 |
++
GSK-3β, Ki: 38 nM |
99%+ | |||||||||||||||||
| Tideglusib |
+
GSK-3β, IC50: 60 nM |
98% | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 |
|
| 描述 | GSK-3 (Glycogen synthase kinase 3) is a serine/threonine protein kinase, consisting of GSK-3α andβsubunit, which plays a key role in many different biological processes including tumorigenesis, cell survival, and developmental patterning. GSK-3 is constitutively active in non-stimulated cells and can negatively regulate canonical Wnt/β-catenin signaling. CHIR 99021 (CT99021)is highly selective aminopyrimidine-derivatived inhibitor of GSK-3 with IC50 of 10nM and 6.7nM for GSK-3α and GSK-3β(measured by kinase assays), respectively, and exhibits >500-fold selectivity for GSK-3 over closely related kinases, such as cdc2[8]Bennett CN, Ross SE, Longo KA, Bajnok L, Hemati N, Johnson KW, Harrison SD, MacDougald OA. Regulation of Wnt signaling during adipogenesis. J Biol Chem. 2002 Aug 23;277(34):30998-1004. doi: 10.1074/jbc.M204527200. Epub 2002 Jun 7. PMID: 12055200. https://pubmed.ncbi.nlm.nih.gov/12055200/. CHIR-99021 can mimic Wnt signaling in preadipocytes. Analysis of cytosolic and membranous fractions show that the free cytosolic -catenin was evaluated in 3T3-L1 preadipocytes treated with 3uM CHIR-99021 for 4 h [4]. Chir-99021 can activate glycogen synthase in cells. The concentrations of CHIR-99021 causing half-maximal glycogen synthase stimulation (EC50) were 76 nmol/l for CHO-IR cells. A single oral dose of CHIR 99021 (30mg/kg) rapidly lowered plasma glucose in ZDF rats[8]. In combination with different small molecules, CHIR-99021 can facilitate cardiomyocyte differentiation from human embryonic stem cells and iPS cells[10][9], reprogramming, like generation of functional astrocytes from mammalian fibroblasts[10] and maintaining undifferentiated mouse ES cells in the absence of LIF[11]. |
| 作用机制 | CHIR 99021 can inhibit GSK3 by competing for their ATP-binding sites. |
| Concentration | Treated Time | Description | References | |
| Cos7 cells | 8 nM | 20 minutes | GSK3 inhibition increases macropinocytosis | Cell Rep. 2020 Jul 28;32(4):107973 |
| MLO-Y4 | 5 µM | 24 hours | Activate Wnt signaling pathway, promote osteogenic differentiation and mineralization of ST2 cells | Int J Mol Sci. 2023 Mar 22;24(6):6008 |
| HaCaT cells | 8 nM | 20 minutes | GSK3 inhibition increases macropinocytosis | Cell Rep. 2020 Jul 28;32(4):107973 |
| mouse embryonic stem cells (mESCs) | 3 μM | 48 hours | To investigate the effect of GSK-3 inhibition on Xist RNA expression, results showed that GSK-3 inhibition caused loss of Xist RNA expression. | Nat Commun. 2022 May 6;13(1):2516 |
| HEK293T cells | 5 or 10 μM | Activate Wnt/β-catenin signaling to a level similar to Wnt plus R-spondin1 | Cell Discov. 2018 Sep 4;4:49. | |
| B cells | 10 µM | 48 h | Induced IL-10+ Bregs and suppressed TNF-α expression | Mol Ther. 2024 Dec 4;32(12):4372-4382. |
| Human induced pluripotent stem cells (hiPSCs) | 8 μM | 3 days | By activating the Wnt signaling pathway, hiPSCs were induced to differentiate into cardiac lateral plate mesoderm cells (hiCLPM). | Circulation. 2024 Apr 30;149(18):1435-1456. |
| Lgr5+ intestinal stem cells | 10 μM | 7 days | Maintain self-renewal and proliferation of Lgr5+ intestinal stem cells | Cell Discov. 2018 Sep 4;4:49. |
| primary murine colonic epithelial cells | 2.5 μM | 48 h | To investigate the impact of Wnt signaling on intracellular Ca2+ oscillation patterns, results showed that CHIR-99021 significantly increased Ca2+ spike frequency and decreased pulse width | Adv Healthc Mater. 2021 Nov;10(22):e2101318. |
| Dose | Rat[3] (p.o.): 16 mg/kg - 48 mg/kg | ||||||||
| Administration | p.o. | ||||||||
| Pharmacokinetics |
|
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
2.15mL 0.43mL 0.21mL |
10.74mL 2.15mL 1.07mL |
21.49mL 4.30mL 2.15mL |
|
| CAS号 | 252917-06-9 |
| 分子式 | C22H18Cl2N8 |
| 分子量 | 465.34 |
| SMILES Code | N#CC1=CN=C(NCCNC2=NC=C(C3=NC=C(C)N3)C(C4=CC=C(Cl)C=C4Cl)=N2)C=C1 |
| MDL No. | MFCD11846251 |
| 别名 | CT99021; Laduviglusib |
| 运输 | 蓝冰 |
| InChI Key | AQGNHMOJWBZFQQ-UHFFFAOYSA-N |
| Pubchem ID | 9956119 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Keep in dark place, inert atmosphere, store in freezer, under -20°C |
| 溶解方案 |
DMSO: 16 mg/mL(34.38 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1